283 related articles for article (PubMed ID: 18220286)
1. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.
Charlton M; Angulo P; Chalasani N; Merriman R; Viker K; Charatcharoenwitthaya P; Sanderson S; Gawrieh S; Krishnan A; Lindor K
Hepatology; 2008 Feb; 47(2):484-92. PubMed ID: 18220286
[TBL] [Abstract][Full Text] [Related]
2. Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients.
Sumida Y; Yonei Y; Kanemasa K; Hara T; Inada Y; Sakai K; Imai S; Hibino S; Yamaguchi K; Mitsuyoshi H; Yasui K; Minami M; Itoh Y; Naito Y; Yoshikawa T; Okanoue T
Hepatol Res; 2010 Sep; 40(9):901-10. PubMed ID: 20887595
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.
Koehler E; Swain J; Sanderson S; Krishnan A; Watt K; Charlton M
Liver Int; 2012 Feb; 32(2):279-86. PubMed ID: 22098614
[TBL] [Abstract][Full Text] [Related]
4. Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
de Araujo Neto JM; Coelho HSM; Chindamo MC; Rezende GFM; Nunes Pannain VL; Bottino AMCF; Bruzzi Porto LF; Luiz RR; Villela-Nogueira CA; Perez RM
J Viral Hepat; 2018 Mar; 25(3):254-261. PubMed ID: 29091323
[TBL] [Abstract][Full Text] [Related]
5. Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease.
Tokushige K; Hashimoto E; Kodama K; Tobari M; Matsushita N; Kogiso T; Taniai M; Torii N; Shiratori K; Nishizaki Y; Ohga T; Ohashi Y; Sato T
J Gastroenterol; 2013 Dec; 48(12):1392-400. PubMed ID: 23478936
[TBL] [Abstract][Full Text] [Related]
6. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.
Kashyap SR; Diab DL; Baker AR; Yerian L; Bajaj H; Gray-McGuire C; Schauer PR; Gupta M; Feldstein AE; Hazen SL; Stein CM
Obesity (Silver Spring); 2009 Sep; 17(9):1696-701. PubMed ID: 19360015
[TBL] [Abstract][Full Text] [Related]
7. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM
Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399
[TBL] [Abstract][Full Text] [Related]
8. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
[TBL] [Abstract][Full Text] [Related]
9. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
[TBL] [Abstract][Full Text] [Related]
10. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.
Yoneda M; Mawatari H; Fujita K; Iida H; Yonemitsu K; Kato S; Takahashi H; Kirikoshi H; Inamori M; Nozaki Y; Abe Y; Kubota K; Saito S; Iwasaki T; Terauchi Y; Togo S; Maeyama S; Nakajima A
J Gastroenterol; 2007 Jul; 42(7):573-82. PubMed ID: 17653654
[TBL] [Abstract][Full Text] [Related]
11. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
[TBL] [Abstract][Full Text] [Related]
12. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
[TBL] [Abstract][Full Text] [Related]
13. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD).
Raszeja-Wyszomirska J; Szymanik B; Ławniczak M; Kajor M; Chwist A; Milkiewicz P; Hartleb M
BMC Gastroenterol; 2010 Jun; 10():67. PubMed ID: 20584330
[TBL] [Abstract][Full Text] [Related]
14. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.
Kowdley KV; Belt P; Wilson LA; Yeh MM; Neuschwander-Tetri BA; Chalasani N; Sanyal AJ; Nelson JE;
Hepatology; 2012 Jan; 55(1):77-85. PubMed ID: 21953442
[TBL] [Abstract][Full Text] [Related]
15. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
Genc H; Dogru T; Kara M; Tapan S; Ercin CN; Acikel C; Karslioglu Y; Bagci S
Ann Hepatol; 2013; 12(4):548-55. PubMed ID: 23813132
[TBL] [Abstract][Full Text] [Related]
16. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
17. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N
J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390
[TBL] [Abstract][Full Text] [Related]
19. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
20. Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis.
Muñoz LE; Cordero P; Torres L; Sauceda AY; Flores JP; Segura JJ
Ann Hepatol; 2009; 8(2):123-8. PubMed ID: 19502655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
